natgillin/translations-raw huggingface dataset:
5 ml vial (type I glass) closed with a stopper (bromobutyl/isoprene polymer) and a seal (lacquered plastic). 
5-ml viala (steklo tipa I), ki je zaprta z zamaškom (bromobutil/izoprenski polimer) in zapečatena (lakirana plastika).
The doctor should regularly examine your tonsils/adenoids. 
Zdravnik mora stanje tonzil/adenoidnega tkiva redno nadzirati.
• That patients should have examinations of the ears, nose and throat periodically and at the occurrence of clinical symptoms to rule out such potential complications or to initiate appropriate treatment. 
• Bolniki morajo imeti redne preglede ušes, nosu in grla in pri pojavu kliničnih simptomov je treba preprečiti tovrstne morebitne zaplete ali začeti z ustreznim zdravljenjem.
Final report by 
Zaključno poročilo do leta
The dose of mecasermin should never be increased to make up for one or more omitted doses. 
Odmerka mekazermina se ne sme nikoli zvišati, da bi se tako nadoknadil eden ali več izpuščenih odmerkov.
If you have scoliosis, you will need to be checked often for an increase in the curve of the spine. 
Če imate skoliozo, bo treba pogosto preverjati morebitno preveliko ukrivljenost hrbtenice.
The effects of mecasermin on the unborn child have not been studied. 
Vplivov mekazermina na nerojenega otroka niso raziskovali.
- if you have symptoms of increased pressure in the brain (intracranial hypertension), such as visual changes, headache, nausea and/or vomiting, contact the doctor for advice. 
- če imate simptome povišanega tlaka v možganih (intrakranialna hipertenzija), kot so spremembe vida, glavobol, slabost in/ali bruhanje, se posvetujte z zdravnikom.
It is recommended that the dose be individualised for each patient as described under posology 
Odmerek je priporočljivo prilagoditi vsakemu bolniku posebej, kot je opisano pod odmerjanjem.
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 40mg/4ml 
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT 40 mg/4 ml
The next dose should be taken as usual, with a meal or snack. 
Naslednjič uporabite običajni odmerek ob običajnem času, skupaj z obrokom hrane ali s prigrizkom.
6.6 Special precautions for disposal and other handling INCRELEX is supplied as a multi-dose solution. 
6.6 Posebni varnostni ukrepi za odstranjevanje in ravnanje z zdravilom Zdravilo INCRELEX je na voljo v obliki večodmerne sterilne raztopine.
Pharmacodynamic effects The following actions have been demonstrated for endogenous human IGF-1: 
Farmakodinamični učinki Dokazani so bili naslednji učinki endogenega humanega IGF-1:
The most frequently reported adverse reactions from the clinical trials were headache (44%), hypoglycaemia (28%), vomiting (26%), injection site hypertrophy (17%), and otitis media (17%). 
V kliničnih preskušanjih so najpogosteje poročali o naslednjih neželenih učinkih: glavobolu (44 %), hipoglikemiji (28 %), bruhanju (26 %), hipertrofiji na mestu injiciranja (17 %) in vnetju srednjega ušesa (17 %).
Pharmacotherapeutic group: Pituitary and hypothalamic hormones and analogues, somatropin and somatropin agonists, ATC code: H01AC03 
Farmakoterapevtska skupina: Hipofizni in hipotalamični hormoni ter sorodne učinkovine, somatropin in sorodne učinkovine, oznaka ATC: H01AC03
Mecasermin may cause hypoglycaemia (very common side effect, see section 4) that may impair your ability to drive and use machines because your ability to concentrate or react may be reduced. 
Mekazermin lahko povzroči hipoglikemijo (zelo pogost neželeni učinek, glejte poglavje 4), ki lahko vpliva na sposobnost koncentracije in reagiranja ter tako zmanjša sposobnost za vožnjo in upravljanje strojev.
The dose of 120 μg/kg given subcutaneously (SC) and twice daily (BID) was associated with the greatest growth responses. 
Odmerek 120 μg/kg subkutano dvakrat na dan je bil povezan z največjim odzivom rasti.
The recommended starting dose of mecasermin is 0.04 mg/kg of body weight twice daily by subcutaneous injection. 
Priporočeni začetni odmerek mekazermina je 0,04 mg/kg telesne mase dvakrat na dan v obliki subkutane injekcije.
If no significant adverse reactions occur for at least one week, the dose may be raised in increments of 0.04 mg/kg to the maximum dose of 0.12 mg/kg given twice daily. 
Če vsaj en teden ne pride do pojava neželenih učinkov, se lahko odmerek postopno povečuje za 0,04 mg/kg do največjega dovoljenega odmerka 0,12 mg/kg dvakrat na dan.
If bubbles are in the syringe, hold the vial and syringe with needle straight up and tap the side of the syringe until the bubbles float to the top. 
Če so mehurčki prisotni v brizgi, pridržite vialo in brizgo z iglo v navpičnem položaju in rahlo udarjajte po brizgi, dokler se mehurčki ne dvignejo na vrh.
- if you have a localised reaction at the injection site or generalised allergic reaction with INCRELEX. 
- če se pojavi reakcija na mestu injiciranja ali splošna alergijska reakcija na zdravilo INCRELEX.
Persons with a history of severe hypoglycemia should have glucagon available. 
Osebe s hudo hipoglikemijo v anamnezi morajo imeti na voljo glukagon.
INCRELEX contains benzyl alcohol as a preservative which may cause toxic reactions and allergic reactions in infants and children up to 3 years old. 
Zdravilo INCRELEX vsebuje kot konzervans benzilalkohol, ki lahko povzroči toksične in alergijske reakcije pri dojenčkih in otrocih do 3. leta starosti.
Pre-treatment height velocity data were available for 75 subjects. 
Podatki o hitrosti rasti pred začetkom zdravljenja so bili na voljo za 75 oseb.
Persons who have allergic reactions to injected IGF-1, who have unexpectedly high blood values of IGF-1 after injection, or who fail to show a growth response without any identified cause may be having an antibody response to injected IGF-1. 
Pri osebah, pri katerih injiciranje IGF-1 povzroči alergijske reakcije, ki imajo po vbrizganju IGF-1 nepričakovano visoko raven IGF-1 v krvi ali se brez kakršnegakoli znanega vzroka ne odzovejo z rastjo, je morda ob vbrizganju IGF-1 prišlo do odziva s protitelesi.
What INCRELEX is and what it is used for 
Kaj je zdravilo INCRELEX in za kaj ga uporabljamo
During clinical trials in other indications (totaling approximately 300 patients) 8% of patients reported a local and/or systemic hypersensitivity reactions. 
Med kliničnimi preskušanji uporabe zdravila pri drugih indikacijah (vsega skupaj pri približno 300 bolnikih) so pri 8 % bolnikov poročali o pojavu lokalnih in/ali sistemskih preobčutljivostnih reakcij.
Only use INCRELEX that is clear and colourless. 
Uporabite le zdravilo INCRELEX, ki je bistro in brezbarvno.
• To educate parents on the signs, symptoms and treatment of hypoglycaemia, including injection of glucagon. 
• Poučiti starše o znakih, simptomih in zdravljenju hipoglikemije, vključno z injekcijo glukagona.
If you are using a new vial, remove the protective cap. Do not remove the rubber stopper. 
Če uporabljate novo vialo, odstranite zaščitni pokrovček.
Some patients may develop antibodies to mecasermin. 
Pri nekaterih bolnikih se lahko pojavijo protitelesa proti mekazerminu.
Severe hypoglycaemia may cause unconsciousness, seizures/fits or death. 
Huda hipoglikemija lahko povzroči nezavest, krče ali smrt.
Adverse reaction data was taken from a total of 413 clinical trial patients with severe Primary IGFD. 
Podatki o neželenih učinkih so bili pridobljeni v kliničnih preskušanjih pri skupno 413 bolnikih s hudim primarnim pomanjkanjem IGF.
In target tissues the Type 1 IGF-1 receptor, which is homologous to the insulin receptor, is activated by IGF-1, leading to intracellular signaling which stimulates multiple processes leading to statural growth. 
V ciljnem tkivu IGF-1 aktivira receptor za IGF-1 tipa 1, ki je homologen z receptorji za insulin, kar pripelje do znotrajceličnega signaliziranja, kar spodbudi številne procese, ki vodijo v telesno rast.
If the patient is not awake or alert enough to drink sugarcontaining fluids, an injection of glucagon into the muscle may be necessary to reverse the low blood sugar. 
Če bolnik ni buden ali dovolj pozoren, da bi lahko požiral tekočino s sladkorjem, bo morda potrebna injekcija glukagona v mišico, da bi se vrednost krvnega sladkorja povečala.
In some patients treated with mecasermin, an ultrasound examination of the heart (echocardiogram) showed an increased size of the heart muscle and abnormalities of heart valve function. 
Pri nekaterih bolnikih, zdravljenih z mekazerminom, je pregled srca z ultrazvokom (ehokardiogram) razkril povečanje srčne mišice in motnje delovanja srčnih zaklopk.
IGF-1 suppresses hepatic glucose production, stimulates peripheral glucose utilization, and can reduce blood glucose and cause hypoglycaemia. 
IGF-1 zavira sintezo glukoze v jetrih in spodbuja porabo glukoze v perifernih tkivih ter lahko zmanjša koncentracijo glukoze v krvi in povzroči hipoglikemijo.
Signs of low blood sugar are: dizziness, tiredness, restlessness, hunger, irritability, trouble concentrating, sweating, nausea and fast or irregular heartbeats. 
Znaki nizkega krvnega sladkorja so: omotica, utrujenost, nemirnost, lakota, razdražljivost, težave s koncentracijo, znojenje, slabost in hitro ali nepravilno bitje srca.
Before you take the needle out of the vial, check the syringe for air bubbles. 
Preden iglo izvlečete iz viale, preverite, če so v brizgi prisotni zračni mehurčki.
• To inform parents and patients that systemic allergic reactions are possible and that if this occurs treatment should be interrupted and prompt medical attention should be sought. 
• Obvestiti starše in bolnike, da so sistemske alergijske reakcije mogoče in da je treba zdravljenje prekiniti ter takoj poiskati ustrezno zdravniško pomoč, če do njih pride.
• Possible occurrence of malignancies as well as other risks The interim reports will be submitted every two years until the final patient is followed for 5 years. 
Vmesna poročila bodo predložena vsaki 2 leti, dokler ne bo zadnji bolnik spremljan 5 let.
INCRELEX should be administered using sterile disposable syringes and injection needles which could be provided by your doctor, pharmacist or nurse. 
Pri injiciranju zdravila INCRELEX morate uporabljati sterilne injekcijske brizge in igle za enkratno uporabo, ki jih lahko dobite pri zdravniku, farmacevtu ali medicinski sestri.
Five clinical studies (4 open-label and 1 double-blind, placebo-controlled) were conducted with INCRELEX. 
Z zdravilom INCRELEX je bilo izvedenih pet kliničnih študij (4 odprte študije in 1 dvojno slepa, s placebom nadzorovana študija).
Inject INCRELEX just under your skin shortly before or after a meal or snack because it may have insulinlike hypoglycaemic effects and so it may decrease blood sugar levels (see hypoglycaemia in section 4). 
Zdravilo INCRELEX si injicirajte pod kožo neposredno pred ali po obroku oziroma prigrizku, saj ima zdravilo lahko insulinu podoben hipoglikemični učinek in lahko zniža vrednost krvnega sladkorja (glejte hipoglikemija v poglavju 4).
This was noted in 38 (9%) subjects, particularly in the first 1 to 2 years of therapy with lesser tonsillar growth in subsequent years. 
O hipertrofiji tonzil so poročali pri 38 osebah (9 %), še posebej v prvem in drugem letu zdravljenja, v kasnejših letih pa je bila pojavnost hipertofije tonzil manjša.
Very common (may affect more than 1 in 10 people) Low blood sugar (hypoglycaemia) 
Zelo pogosti neželeni učinki (pojavijo se lahko pri več kot 1 od 10 bolnikov) Nizek krvni sladkor (hipoglikemija)
As INCRELEX contains benzyl alcohol, it must not be given to premature babies or neonates. 
Zdravilo INCRELEX vsebuje benzilalkohol, zato se ga ne sme dajati nedonošenčkom ali novorojenčkom.
Pregnancy There are no or limited amount of data for the use of mecasermin in pregnant women. 
Nosečnost Podatkov o uporabi mekazermina pri nosečnicah ni oziroma so omejeni.
The symptoms of intracranial hypertension can include visual changes, headache, nausea and/or vomiting. 
Simptomi intrakranialne hipertenzije lahko vključujejo spremembe vida, glavobol, slabost in/ali bruhanje.
Mecasermin, like insulin, may lower blood sugar levels (see hypoglycaemia in section 4). 
Mekazermin lahko, podobno kot insulin, zniža vrednost krvnega sladkorja (glejte hipoglikemija v poglavju 4).
Common: Skin hypertrophy, abnormal hair texture 
Pogosti: hipertrofija kože, nenormalna tekstura las
Push the bubbles out with the plunger and draw liquid back in until you have the correct dose (see Figure 6). 
Mehurčke iztisnite s pomočjo bata in tekočino znova izvlecite, dokler ne izvlečete ustreznega odmerka (glejte sliko 6).
In adolescents with Primary IGFD and in healthy adults there were no apparent differences between males and females in the pharmacokinetics of INCRELEX. 
Pri mladostnikih s primarnim pomanjkanjem IGF in pri zdravih odraslih se farmakokinetika zdravila INCRELEX med osebami moškega in ženskega spola ni pomembneje razlikovala.
- The other ingredients are: benzyl alcohol, sodium chloride, polysorbate 20, glacial acetic acid, sodium acetate and water for injections (see section 2 "INCRELEX contains benzyl alcohol and sodium"). 
- Druge sestavine zdravila so: benzilalkohol, natrijev klorid, polisorbat 20, koncentrirana ocetna kislina (ledocet), natrijev acetat in voda za injekcije (glejte poglavje 2 “Zdravilo INCRELEX vsebuje benzilalkohol in natrij”).
After first use, the vial may be stored for up to 30 days at 2C to 8ºC. 
Po prvi uporabi lahko vialo shranjujete do 30 dni pri temperaturi od 2C - 8 ºC.
Make sure the tip of the needle is in the liquid (see Figure 4). 
Prepričajte se, da je konica igle v tekočini (glejte sliko 4).
Of these, 72 (89%) had Laron syndrome-like phenotype; 7 (9%) had GH gene deletion, 1 (1%) had neutralizing antibodies to GH and 1 (1%) had isolated genetic GH deficiency. 
Od teh je 72 oseb (89 %) imelo fenotip, podoben Laronovemu sindromu, 7 oseb (9 %) delecijo gena za GH, 1 oseba (1 %) nevtralizirajoča protitelesa proti GH in 1 oseba (1 %) izolirano genetsko pomanjkanje GH. 46 oseb (57 %) je bilo moškega spola in 66 oseb (81 %) belcev.
What you need to know before you use INCRELEX 3. 
Kaj morate vedeti, preden boste uporabili zdravilo INCRELEX
Very common: Headache Common: Convulsions, dizziness, tremor 
Zelo pogosti: glavobol Pogosti: konvulzije, omotica, tremor
For severe hypoglycaemia, if you are not responsive and cannot drink sugar-containing fluids, you should give an injection of glucagon. 
V primeru hude hipoglikemije, ko se več ne odzivate in ne morete zaužiti tekočine s sladkorjem, vam morajo dati injekcijo glukagona.
• Immunogenicity sampling information. 
• Informacije o vzorčenju imunogenih lastnosti.
The rhIGF-1 protein is synthesised in bacteria (E. coli) that have been modified by the addition of the gene for human IGF-1. 
Sinteza proteina rhIGF-1 poteka v bakterijah (E. coli), ki imajo vstavljen gen za humani IGF-1.
Organ growth: treatment of IGF-1 deficient rats with rhIGF-1 results in whole body and organ growth. 
Rast organov: pri dajanju rhIGF-1 podganam s pomanjkanjem IGF-1 so zasledili rast tako celotnega telesa kot organov.
In this case INCRELEX cannot help you grow and should not be used. 
V tem primeru vam zdravljenje z zdravilom INCRELEX ne bo koristilo, zato zdravila ne smete uporabljati.
65, quai Georges Gorse 92100 Boulogne-Billancourt France 
65, quai Georges Gorse 92100 Boulogne-Billancourt Francija
There were also reports of systemic hypersensitivity from post-marketing use, of which some cases were indicative of anaphylaxis. 
O sistemski preobčutljivosti so poročali tudi v obdobju po začetku trženja zdravila, nekatera od teh poročil pa so kazala na anafilaksijo.
INCRELEX contains benzyl alcohol and sodium 
Zdravilo INCRELEX vsebuje benzilalkohol in natrij
It is also recommended that all women of childbearing potential use adequate contraception during treatment. 
Za vse ženske v rodni dobi je priporočljivo, da med zdravljenjem uporabljajo učinkovito kontracepcijo.
At the time of initial prescription, physicians should educate parents on the signs, symptoms and treatment of hypoglycaemia, including injection of glucagon. 
Na začetku zdravljenja je potrebno starše poučiti o znakih, simptomih in zdravljenju hipoglikemije, vključno z injiciranjem glukagona.
A small number of cases indicative of anaphylaxis requiring hospitalisation have been reported. 
V majhnem številu primerov so poročali o anafilaksiji, pri kateri je bilo potrebno zdravljenje v bolnišnici.
Before putting the needle into the vial, pull back on plunger to draw air into the syringe equal to the prescribed dose. 
Preden iglo zabodete v vialo, bat brizge izvlecite nazaj in brizgo napolnite z zrakom do oznake, ki ustreza predpisanemu odmerku zdravila.
Throw them away properly in a sharps container (such as a biohazard container), hard plastic container (such as a detergent bottle), or metal container (such as an empty coffee can). 
Po uporabi ju ustrezno zavrzite v zabojnik za odlaganje ostrih predmetov (kot je posoda za biološko nevarne odpadke), trdo plastično posodo (kot je plastenka od detergenta) ali kovinsko posodo (kot je prazna kovinska posoda za kavo).
Tonsillar hypertrophy 
Hipertrofija tonzil
Not known: Systemic hypersensitivity (anaphylaxis, generalized urticaria, angioedema, dyspnoea), local allergic reactions at the injection site (pruritus, urticaria) 
Neznana pogostnost: sistemska preobčutljivost (anafilaksija, generalizirana urtikarija, angioedem, dispneja), lokalne alergijske reakcije na mestu injiciranja (srbenje, urtikarija)
The metabolic actions of IGF-1 are in part directed at stimulating the uptake of glucose, fatty acids, and amino acids so that metabolism supports growing tissues. 
Presnovno delovanje IGF-1 je deloma usmerjeno k spodbujanju privzema glukoze, maščobnih kislin in aminokislin, tako da presnova oskrbuje rastoča tkiva.
In rats and rabbits reproductive toxicity was studied after intravenous but not after subcutaneous application (the normal clinical route). 
Pri podganah in kuncih so vpliv na sposobnost razmnoževanja raziskovali po intravenskem dajanju, ne pa tudi po subkutanem, ki je običajni način dajanja pri klinični uporabi.
Mecasermin may lower blood sugar levels. 
Mekazermin lahko zniža nivo krvnega sladkorja.
Your doctor or nurse will instruct you how to give the injection of glucagon. 
Zdravnik ali medicinska sestra vas bosta poučila, kako injicirati glukagon.
Mecasermin was administered subcutaneously to Sprague Dawley rats at doses of 0, 0.25, 1, 4, and 10 mg/kg/day for up to 2 years. 
Podgane vrste Sprague Dawley so do dve leti prejemale mekazermin subkutano v odmerkih 0; 0,25; 1; 4 in 10 mg/kg/dan.
Any patient with the onset of a limp or complaint of hip or knee pain should be evaluated. 
Vsakega bolnika, ki začne šepati ali toži zaradi bolečin v kolkih ali kolenih, je treba ustrezno pregledati.
The MAH must ensure that, at launch, all physicians who are expected to prescribe INCRELEX are provided with a “physician information pack” containing the following: 
Imetnik dovoljenja za promet mora zagotoviti, da imajo vsi zdravniki, ki bodo predvidoma predpisovali zdravilo INCRELEX, že ob prihodu zdravila na trg na voljo gradivo o zdravilu, ki vsebuje naslednje:
Figure 2: Inject air into vial 
Slika 2: V vialo iztisnite zrak
Patients should have examinations periodically and at the occurrence of clinical symptoms to rule out such potential complications or to initiate appropriate treatment. 
Bolniki morajo redno hoditi na preglede in ob pojavu kliničnih simptomov je potrebno te zaplete preprečiti oziroma uvesti ustrezno zdravljenje.
During clinical trials in other indications totalling approximately 300 patients, reports of local and/or systemic hypersensitivity were received for 8% of patients. 
Med kliničnimi preskušanji uporabe zdravila pri drugih indikacijah, ki so bila izvedena pri vsega skupaj približno 300 bolnikih, so pri 8 % bolnikov poročali o pojavu lokalne in/ali sistemske preobčutljivosti.
Inject INCRELEX as instructed by the doctor. 
Zdravilo INCRELEX injicirajte, kot vam je pokazal zdravnik.
Put the needle through the rubber top of the vial and push the plunger to inject air into the vial (see Figure 2). 
Iglo zabodite skozi gumijasti vrh viale in pritisnite na bat ter zrak iztisnite v vialo (glejte sliko 2).
Figure 4: Tip in liquid 
Slika 4: Konica v tekočini
One ml contains 9 mg of benzyl alcohol. 
En mililiter vsebuje 9 mg benzilalkohola.
IGF-1 consists of 70 amino acids in a single chain with three intramolecular disulfide bridges and a molecular weight of 7649 daltons. 
IGF-1 sestavlja 70 aminokislin v eni verigi s tremi intramolekularnimi disulfidnimi mostički.
Such containers should be sealed and disposed of properly in the way your doctor described. 
Takšne posode morate dobro zapreti in nato ustrezno zavreči v skladu z zdravnikovimi navodili.
If you forget to use INCRELEX 
Če ste pozabili uporabiti zdravilo INCRELEX
If you stop using INCRELEX 
Če ste prenehali uporabljati zdravilo INCRELEX
Treatment with mecasermin is a long-term therapy. 
Mekazermin je namenjen dolgotrajnemu zdravljenju.
Hypoglycaemia was the most frequently reported adverse event and a proper attention has to be given to meals in relation to dosing. 
Hipoglikemija je bila najpogosteje poročani neželeni učinek, zato je posebno pozornost treba nameniti uporabi zdravila v času obrokov.
INCRELEX should be administered by subcutaneous injection shortly before or after a meal or snack. 
Zdravilo INCRELEX je treba uporabljati v obliki subkutane injekcije neposredno pred ali po obroku oziroma prigrizku.
Toxicity to reproduction 
Vpliv na sposobnost razmnoževanja
Treatment of acute overdose of mecasermin should be directed at alleviating any hypoglycaemic effects. 
Zdravljenje akutnega prevelikega odmerjanja mekazermina mora biti usmerjeno k ublažitvi hipoglikemičnih učinkov.
Parents and patients should be informed that such reactions are possible and that if a systemic allergic reaction occurs, treatment should be interrupted and prompt medical attention should be sought. 
Starše in bolnike je treba opozoriti na možnost pojava tovrstnih reakcij in da morajo v primeru pojava sistemske alergijske reakcije zdravljenje takoj opustiti ter nemudoma poiskati zdravniško pomoč.
The patient information about INCRELEX should contain the following information: 
Vodnik za bolnika o zdravilu INCRELEX mora vsebovati naslednje informacije:
Some signs of enlarged tonsils/adenoids include: snoring, difficulty breathing or swallowing, sleep apnoea (a condition where breathing stops briefly during sleep), or fluid in the middle ear, as well as infections of the ear. 
Nekateri znaki povečanja tonzil/adenoidnega tkiva so: smrčanje, težave pri dihanju ali požiranju, apneja v spanju (začasno prenehanje dihanja med spanjem) ali tekočina v srednjem ušesu ter tudi okužbe ušesa.
INCRELEX should not be administered intravenously. 
Zdravila INCRELEX se ne sme uporabljati intravensko.
Other uncommon side effects seen with mecasermin treatment include depression, nervousness. 
Druga občasna neželena učinka mekazermina sta depresija in živčnost.
The most frequently occurring side effects with mecasermin are: low blood sugar (hypoglycemia), vomiting, injection site reactions, headache and middle ear infections. 
Najpogostejši neželeni učinki mekazermina so: nizek krvni sladkor (hipoglikemija), bruhanje, reakcije na mestu injiciranja, glavobol in okužba srednjega ušesa.
Clinical Trial 
Klinično preskušanje
• That INCRELEX should be administered shortly before or after a meal or snack because it has insulin-like hypoglycaemic effects. 
• Zdravilo INCRELEX je treba dati neposredno pred ali po obroku oziroma prigrizku, saj ima insulinu podobne hipoglikemične učinke.
From a microbiological point of view, once opened, the medicinal product may be stored for a maximum of 30 days at 2C to 8C. 
Iz mikrobiološkega vidika se sme zdravilo po odprtju hraniti največ 30 dni pri temperaturi od 2 C - 8 C.
Chemical and physical in-use stability has been demonstrated for 30 days at 2C to 8C. 
Dokazano je bilo, da je zdravilo med uporabo kemično in fizikalno stabilno 30 dni, če se ga shranjuje pri temperaturi od 2 C - 8 C.
Hypoglycaemia is a very common adverse reaction. 
Hipoglikemija je zelo pogost neželeni učinek.